Optimal Design of Drug-Drug Interaction Studies for the GLP-1 Receptor Agonist Drug Class for Weight Management: Closing a Potential Data Gap

被引：0
|
作者：
Weber, Elijah [1 ]
Trivedi, Ashit [2 ]
Barbour, April M. [1 ]
机构：
[1] AstraZeneca, Clin Pharmacol & Quantitat Pharmacol, Clin Pharmacol & Safety Sci, R&D, Gaithersburg, MD USA
[2] AstraZeneca, Clin Pharmacol & Quantitat Pharmacol, Clin Pharmacol & Safety Sci, R&D, Waltham, MA USA
来源：
JOURNAL OF CLINICAL PHARMACOLOGY | 2025年
关键词：
clinical pharmacology study design; drug-drug interaction; gastric-emptying delay; GLP-1; RA; oral contraceptive;
D O I：
10.1002/jcph.70020
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页数：3
相关论文
共 35 条
  • [31] SGLT2 Inhibitor and GLP-1 Receptor Agonist Combination Therapy Substantially Improved the Renal Function in a Patient with Type 2 Diabetes: Implications for Additive Renoprotective Effects of the Two Drug Classes
    Nonomura, Kenta
    Iizuka, Katsumi
    Kuwabara-Ohmura, Yayoi
    Yabe, Daisuke
    INTERNAL MEDICINE, 2020, 59 (12) : 1535 - 1539
  • [32] Clinical Impact of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Uncontrolled Type 2 Diabetes and Very High Baseline HbA1c: The FREEDOM-1 HBL (High Baseline) Study
    Henry, Robert R.
    Rosenstock, Julio
    Denham, Douglas S.
    Prabhakar, Prakash
    Kjems, Lise
    Baron, Michelle A.
    DIABETES CARE, 2018, 41 (03) : 613 - 619
  • [33] Ecological momentary assessment and cue-elicited drug craving as primary endpoints: study protocol for a randomized, double-blind, placebo-controlled clinical trial testing the efficacy of a GLP-1 receptor agonist in opioid use disorder
    Freet, Christopher S.
    Evans, Brianna
    Brick, Timothy R.
    Deneke, Erin
    Wasserman, Emily J.
    Ballard, Sarah M.
    Stankoski, Dean M.
    Kong, Lan
    Raja-Khan, Nazia
    Nyland, Jennifer E.
    Arnold, Amy C.
    Krishnamurthy, Venkatesh Basappa
    Fernandez-Mendoza, Julio
    Cleveland, H. Harrington
    Scioli, Adam D.
    Molchanow, Amanda
    Messner, Amy E.
    Ayaz, Hasan
    Grigson, Patricia S.
    Bunce, Scott C.
    ADDICTION SCIENCE & CLINICAL PRACTICE, 2024, 19 (01):
  • [34] Discovery of 1-[1-(1-Methylcyclooctyl)-4-piperidinyl]-2-[(3R)-3-piperidinyl]-1H-benzimidazole: Integrated Drug-Design and Structure-Activity Relationships for Orally Potent, Metabolically Stable and Potential-Risk Reduced Novel Non-Peptide Nociceptin/Orphanin FQ Receptor Agonist as Antianxiety Drug
    Hayashi, Shigeo
    Hirao, Akiko
    Nakamura, Hiroshi
    Yamamura, Kenzo
    Mizuno, Kunihiko
    Yamashita, Hiroyo
    CHEMICAL BIOLOGY & DRUG DESIGN, 2009, 74 (04) : 369 - 381
  • [35] ASC41, A THYROID HORMONE RECEPTOR. AGONIST, SHOWED LITTLE DRUG INTERACTION, SIGNIFICANT LIPID REDUCTION AND COMPARABLE PHARMACOKINETIC PROFILES AMONG CHINESE AND US HEALTHY SUBJECTS AND PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD): RESULTS FROM TWO PHASE 1 STUDIES
    Wu, Jinzi
    He, Handan
    Yan, Yuemei
    HEPATOLOGY, 2023, 78 : S1153 - S1154
1234